Palumbo_subbed 25/3/09 11:50 am Page 73
Management of Multiple Myeloma
Bortezomib bortezomib plus PLD for patients who have received at least one
A phase III trial comparing bortezomib and HD reported a significant previous therapy (not including bortezomib). Combination including
improvement in TTP and one-year OS in bortezomib-treated patients;
48
chemotherapy regimes has shown higher RRs in comparison with
and the addition of dexamethasone was associated with improved dexamethasone alone. A chemotherapy agent should be added in the
responses.
49
A phase III trial comparing PAD with bortezomib alone presence of a suboptimal response to new drugs with steroids; a
showed that the use of the drug combination significantly extends sequential approach should be adopted, alternating different drugs
both TTP and OS.
50
The FDA has approved a regimen consisting of following subsequent relapses. ■
1. Kyle RA, Rajkumar SV, Multiple Myeloma, N Engl J Med, multiple myeloma: A placebo controlled randomized phase 3 35. Cavo M, Patriarca F, Tacchetti P, et al., Bortezomib
2004;351:1860–73. trial, Blood, 2007;110:78a. (VELCADE)-Thalidomide-Dexamethasone (VTD) vs Thalidomide-
2. Rajkumar SV, Kyle RA, Multiple Myeloma: Diagnosis and 20. Gareth J, Morgan, Faith E, et al., Thalidomide Combinations Dexamethasone (TD) in preparation for autologous stem-cell
Treatment, Mayo Clin Proc, 2005;80:1371–82. Improve Response Rates; Results from the MRC IX Study, (SC) transplantation (ASCT) in newly diagnosed multiple
3. Ries LAG, Eisner MP, Kosary CL, et al. (eds), SEER cancer Blood, 2007;110:3593. myeloma (MM), Blood, 2007;110:73a.
statistics review, 1975–2000, National Cancer Institute, 21. Palumbo A, Falco P, Corradini P, et al., Melphalan, 36. Popat R, Oakervee HE, Hallam S, et al., Bortezomib,
accessed September 7, 2004. Available at: http//seer.cancer. Prednisone, and Lenalidomide Treatment for newly diagnosed doxorubicin and dexamethasone (PAD) front-line treatment of
gov//csr/1975_2001 myeloma: a report from the GIMEMA-Italian Multiple Myeloma multiple myeloma: updated results after long-term follow-up,
4. Alexander DD, Mink PJ, Adami HO, et al., Multiple myeloma: a Network, J Clin Oncol, 2007;25(28):4459–65. Br J Haematol, 2008;141:512–16.
review of the epidemiologic literature, Int J Cancer, 2007; 22. Mateos MV, Hernandez JM, Hernandez MT, et al., Bortezomib 37. Jakubowiak AJ, Al-Zoubi A, Kendall T, et al., Combination
120(Suppl. 12):40–61. plus melphalan and prednisone in elderly untreated patients therapy with bortezomib (VELCADE), Doxil, and
5. San Miguel JF, Bladé Creixenti J, García-Sanz R, Treatment of with multiple myeloma: results of a multicenter phase I/II dexamethasone (VDD) in newly diagnosed myeloma: updated
multiple myeloma, Haematologica, 1999;84(1):36–58. study, Blood, 2006;108:2165–72. results of phase II clinical trial, Haematologica,
6. Attal M, Harousseau JL, Stoppa AM, et al., A prospective, 23. Mateos M-V, Hernàndez J-M, Hernàndez M-T, et al., 2007;92:180–81.
randomized trial of autologous bone marrow transplantation Bortezomib plus melphalan and prednisone in elderly 38. Palumbo A, Avonto I, Patriarca F, et al., Bortezomib,
and chemotherapy in multiple myeloma. Intergroupe Français untreated patients with multiple myeloma: updated time-to- pegylated-liposomal-doxorubicin and dexamethasone followed
du Myélome, N Engl J Med, 1996;335(2):91–7. events results and prognostic factors for time to progression, by melphalan 100 mg/m2 in elderly newly diagnosed patients:
7 Child JA, Morgan GJ, Davies FE, et al., High-dose Haematologica, 2008;93:560–65. an interim analysis, Blood, 2007;110:448a.
chemotherapy with hematopoietic stem-cell rescue for multiple 24. San Miguel JF, Schlag R, Khuageva NK, et al., Bortezomib plus 39. Attal M, Harousseau JL, Leyvraz S, et al., Maintenance therapy
myeloma, melphalan and prednisone for initial treatment of multiple with thalidomide improves survival in patients with multiple
N Engl J Med, 2003;348(19):1875–83. myeloma, N Engl J Med, 2008;359(9):906–17. myeloma, Blood, 2006;108(10):3289–94.
8. Kumar SK, Rajkumar SV, Dispenzieri A, et al., Improved 25. Macro M, Divine M, Uzunhan Y, et al., Dexamethasone + 40. Spencer A, Prince M, Roberts AW, et al., First Analysis of the
survival in multiple myeloma and the impact of novel Thalidomide (Dex/Thal) Compared to VAD as a Pre-Transplant Australasian Leukaemia and Lymphoma Group (ALLG) Trial of
therapies, Blood, 2008;111(5):2516–20. Treatment in Newly Diagnosed Multiple Myeloma (MM): A Thalidomide and Alternate Day Prednisolone Following
9. Phekoo KJ, Schey SA, Richards MA, et al., A population study Randomized Trial, Blood, 2006;108:57. Autologous Stem Cell Transplantation (ASCT) for Patients with
to define the incidence and survival of multiple myeloma in a 26. Barlogie B, Tricot G, Anaissie E, et al., Thalidomide and Multiple Myeloma (ALLG MM6), Blood, 2006;108:58a.
National Health Service Region in UK, Br J Haematol, 2004; hematopoietic-cell transplantation for multiple myeloma, 41. Abdelkefi A, Ladeb S, Torjman L, et al., Single autologous
127:299–304. N Engl J Med, 2006;354;1021–30. stem-cell transplantation followed by maintenance therapy
10. Kyle RA, Gertz MA, Witzig TE, et al., Review of 1027 patients 27. Lokhorst HM, Schmidt-Wolf I, Sonneveld P, et al., Thalidomide with thalidomide is superior to double autologous
with newly diagnosed multiple myeloma, Mayo Clin Proc, in induction treatment increases the very good partial response transplantation in multiple myeloma: results of a multicenter
2003;78(1):21–33. rate before and after high-dose therapy in previously untreated randomized clinical trial, Blood, 2008;111(4):1805–10.
11. Blade J, Munoz M, Fontanillas M, et al., Treatment of multiple multiple myeloma, Haematologica, 2008;93:124–7. 42. Fermand JP, Jaccard A, Macro M, et al., A randomized
myeloma in elderly people: Long-term results in 178 patients, 28. Palumbo A, Rajkumar SV, Dimopoulos MA, et al., Prevention comparison of dexamethasone + thalidomide (Dex/Thal) vs
Age Ageing, 1996;25:357–61. of thalidomide-associated thrombosis in myeloma, Leukemia, Dex + Placebo (Dex/P) in patients (pts) with relapsing multiple
12. Mileshkin L, Prince HM, The adverse prognostic impact of 2008;22(2):414–23. myeloma (MM), Blood, 2006;108:3563a.
advanced age in multiple myeloma, Leuk Lymphoma, 2005; 29. Zonder JA, Crowley J, Hussein MA, et al., Superiority of 43. Garcia-Sanz R, Gonzalez-Porras JR, Hernandez JM, et al., The
46:951–66. Lenalidomide (Len) plus high-dose dexamethasone (HD) oral combination of thalidomide, cyclophosphamide and
13. Palumbo A, Bringhen S, Petrucci MT, et al., Intermediate-dose compared to HD alone as treatment of newly diagnosed dexamethasone (ThaCyDex) is effective in relapsed/refractory
melphalan improves survival of myeloma patients aged 50 to multiple myeloma (NDMM): results of the randomized, double- multiple myeloma, Leukemia, 2004;18:856–63.
70: results of a randomized controlled trial, Blood, 2004;104 blinded, placebo-controlled SWOG Trial S0232, Blood, 2007; 44. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus
(10):3052–7. 77a. dexamethasone for relapsed multiple myeloma in North
14. Facon T, Mary JY, Hulin C, et al., Melphalan and prednisone 30. Rajkumar SV, Jacobus S, Callander N, et al., A Randomized America, N Engl J Med, 2007;357:2133–42.
plus thalidomide versus melphalan and prednisone alone or Phase III Trial of Lenalidomide Plus High-Dose Dexamethasone 45. Dimopoulos M, Spencer A, Attal M, et al., Lenalidomide plus
reduced-intensity autologous stem cell transplantation in Versus Lenalidomide Plus Low-Dose Dexamethasone in Newly dexamethasone for relapsed or refractory multiple myeloma,
elderly patients with multiple myeloma (IFM 99-06): a Diagnosed Multiple Myeloma (E4A03): A Trial Coordinated by N Engl J Med, 2007;357:2123–32.
randomised trial, Lancet, 2007;370(9594):1209–18. the Eastern Cooperative Oncology Group, Blood, 2006;108: 46. Knop S, Gerecke C, Liebisch P, et al., The efficacy and toxicity
15. Rajkumar SV, Rosiñol L, Hussein M, et al., Multicenter, 799. of the RAD regimen (Revlimid
®
), Adriamycin
®
,
randomized, double-blind, placebo-controlled study of 31. Niesvizky R, Jayabalan DS, Christos PJ, et al., BiRD (Biaxin Dexamethasone) in relapsed and refractory multiple myeloma -
thalidomide plus dexamethasone compared with [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) a phase I/II Trial of “Deutsche Studiengruppe Multiples
dexamethasone as initial therapy for newly diagnosed multiple combination therapy results in high complete- and overall- Myelom”, Blood, 2007;110:2716a.
myeloma, J Clin Oncol, 2008;26:2171–7. response rates in treatment-naive symptomatic multiple 47. Morgan GJ, Schey SA, Wu P, et al., Lenalidomide (Revlimid), in
16. Ludwig H, Tothova E, Hajek R, et al., Thalidomide- myeloma, Blood, 2008;111(3):1101–9. combination with cyclophosphamide and dexamethasone
dexamethasone versus melphalan-prednisolone as first line 32. Harousseau J, Attal M, Leleu X, et al., Bortezomib plus (RCD), is an effective and tolerated regimen for myeloma
treatment in elderly patients with multiple myeloma: second dexamethasone as induction treatment prior to autologous patients, Br J Haematol, 2007;137:268–9.
interim analysis, Haematologica, 2007;92(s1);446a. stem cell transplantation in patients with newly diagnosed 48. Richardson PG, Sonneveld P, Schuster MW, et al., Bortezomib
17. Palumbo A, Bringhen S, Caravita T, et al., Oral melphalan and multiple myeloma: results of an IFM phase II study, or high-dose dexamethasone for relapsed multiple myeloma,
prednisone chemotherapy plus thalidomide compared with Haematologica, 2006;91:1498–1505. N Engl J Med, 2005;352:2487–98.
melphalan and prednisone alone in elderly patients with 33. Rosinol L, Oriol A, Mateos MV, et al., Phase II PETHEMA trial 49. Jagannath S, Richardson PG, Barlogie B, et al., Bortezomib in
multiple myeloma: randomised controlled trial, Lancet, 2006; of alternating bortezomib and dexamethasone as induction combination with dexamethasone for the treatment of patients
367:825–31. regimen before autologous stem-cell transplantation in with relapsed and/or refractory multiple myeloma with less
18. Hulin C, Facon T, Rodon P, et al., Melphalan-prednisone- younger patients with multiple myeloma: efficacy and clinical than optimal response to bortezomib alone, Haematologica,
thalidomide (MP-T) demonstrates a significant survival implications of tumor response kinetics, J Clin Oncol, 2007; 2006;91:929–34.
advantage in elderly patients 75 Years with multiple myeloma 25(28):4452–8. 50. Orlowski RZ, Nagler A, Sonneveld P, et al., Randomized phase
compared with melphalan-prednisone (MP) in a randomized, 34. Harousseau JL, Mathiot C, Attal M, et al., VELCADE/ III study of pegylated liposomal doxorubicin plus bortezomib
double-blind, placebo-controlled trial, IFM 01/01, Blood, 2007; Dexamethasone (Vel/D) Versus VAD as Induction Treatment compared with bortezomib alone in relapsed or refractory
110:75a. Prior to Autologous Stem Cell Transplantion (ASCT) in Newly multiple myeloma: combination therapy improves time to
19. Waage A, Gimsing P, Juliusson G, et al., Melphalan- Diagnosed Multiple Myeloma (MM): Updated Results of the progression, J Clin Oncol, 2007;25:3892–3901.
prednisone-thalidomide to newly diagnosed patients with IFM 2005/01 Trial, Blood, 2007;110:450.
ASIA-PACIFIC ONCOLOGY & HAEMATOLOGY 73
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100